The 14th SAPA-NE Annual Conference 2012

Science, Innovation, and Emerging Markets: Reshaping the Future of the Biopharma Industry

Saturday, June 16th, 2012
Wong Auditorium, Tang Center, Building E51, Sloan School of Management
Massachusetts Institute of Technology, Cambridge, MA 02139

Organizer: SAPA-NE www.SAPA-NEweb.org
Conference Organizers

Conference Chair:
Liqiang Derek Tou, MD, PhD, MBA  SAPA-NE, President-Elect, Millennium/Takeda

Co-Chairs/Moderators:
Min Chen, PhD  SAPA-NE, President, Novartis
Huo Li, PhD  SAPA-NE, Immediate Past President, Biogen-Idec
Xiaotian Zhong, PhD  SAPA-NE, Past President, SAPA Secretary General, Pfizer
Qingcong Lin, PhD  SAPA-NE, Secretary General, Pfizer
Johnny Yang, PhD  SAPA-NE, Executive Committee member, Millennium/Takeda
Xiang Niu, MBA, M.S.  SAPA-NE, Executive Committee member, Avecia Biotech
Jiali Chen, M.D. MBA  SAPA-NE, Executive Committee member, Pfizer
Jiang Long, PhD  SAPA-NE, Executive Committee member, Enanta Pharma
Jie Zhao, M.D., PhD  SAPA-NE, Executive Committee member, MGH
Guoqing Liang, PhD  SAPA-NE, Executive Committee member, Novartis
Wenlai Zhou, Ph.D  SAPA-NE, Executive Committee member, Novartis

Organizing Committee Members:
Daming Gou, PhD  SAPA, Board of Director member, Johnson Mattey Pharma
Bingli Ma, M.D.  SAPA, Board of Director member, Millennium/Takeda
Dapeng Chen, PhD  SAPA-NE, Executive Committee member, Novartis
Dongli Chen, PhD  SAPA-NE, Executive Committee member, Epix Pharma
Weijun Ma, MBA, M.S.  SAPA-NE, Executive Committee member, Pfizer
Wenge Wang, PhD  SAPA-NE, Executive Committee member, Pfizer
Jun Zhao, M.S.  SAPA-NE, Executive Committee member, Merck
Tianxiao Sun, PhD  SAPA-NE, Executive Committee member, Merck
Jinhua Zhang, M.S.  SAPA-NE, Executive Committee member, Genzyme
Yi (Ian) Liu, J.D. PhD  SAPA-NE, Executive Committee member, Finnegan, LLP
Jiaquan Wu, PhD  SAPA-NE, Executive Committee member, AstraZeneca
Yide Jiang, PhD  SAPA-NE, Executive Committee member, Genzyme/Aventis
Youdan (Kelsey) Wang, M.S.  SAPA-NE, Executive Committee member, Brown University
Gaozhong Zhu, PhD  SAPA-NE, Executive Committee member, Shire HGT
Zhiwei Pan, PhD  SAPA-NE, Executive Committee member, Shire HGT
Yuxun Wang, M.D. PhD  SAPA-NE, Executive Committee member, Metamark Genetics
Lan Yang, M.S.  SAPA-NE, Executive Committee member, Genzyme/Sanofi
Huamao Mark Lin, PhD  SAPA-NE, Advisory Committee member, Millennium/Takeda
Jenny Li, M.S.  SAPA-NE, Advisory Committee member, Pfizer
Yongchun Shen, PhD  SAPA-NE, Advisory Committee member, Eisai Research
Huimin Chen, PhD  SAPA-NE, Advisory Committee member, GSK
Ken Li, MBA, M.S.  SAPA-NE, Advisory Committee member, Mingxin Growth Fund
Greetings from the Conference Chair

Dear distinguished speakers, ladies and gentlemen, SAPA Members,

On behalf of the Sino-American Pharmaceutical Professionals Association-New England (SAPA-NE), I am pleased to welcome you to the 14th SAPA-NE Annual Conference. The theme of this special event is "Science, Innovation, and Emerging Markets: Reshaping the Future of the Biopharma Industry".

The pharmaceutical landscape is rapidly changing on a global scale. Big biopharma is facing unprecedented challenges due to various factors, such as patent expiration of blockbuster drugs, higher R&D cost, and economic downturn, therefore it is increasingly chasing opportunities in new emerging markets like China and India; In the other part of the world, with two decades of economic growth and a population of 1.3 billion people, technically savvy returnees, the increased investment by the Chinese government, and improved intellectual property environment, innovative drug R&D is on the rise in China. Novel drugs completely developed by Chinese companies are likely to be marketed worldwide in the near future. Multinational pharmaceutical companies are actively setting R&D centers in China to complement their existing R&D capabilities, and facilitate collaborations with scientists across Western counties and emerging market. The conference serves as a platform for biopharma industry executives, successful entrepreneurs, investors and many other experts to interactively explore and address the opportunities and challenges.

Together, we can bridge. Thanks to the great efforts of our conference committee and the support of our distinguished speakers and panelists, we have the privilege to present you with a wonderful program that captures those critical issues. In the section “Science, innovation in the global market”, Dr. Rosenblatt (Merck), Dr. JC Gutierrez-Ramos (Pfizer) and Dr. Karin Briner (Novartis) will discuss new R&D strategies including China opportunities for the industry. In “Business development in the emerging market”, Ms. Anna Protopapas (Millennium/Takeda), Dr. Peng Wang (Simcere) and Dr. Donald Bergstrom (Sanofi) will focus more on the global business strategy and share their visions on how big pharma can break into the Chinese market. This year we also put lots of emphasis on the two panel forums covering how big pharma can seize the China opportunity and how Chinese returnee entrepreneurs can reshape the future of China. Furthermore, what will make this annual meeting special is that Zhejiang afternoon Overseas High-level Talents Exchange and Cooperation Events will happen at Walker MIT Morss Hall. The conference will be followed by a dinner banquet “Zhejiang night” for you to enjoy the excellent networking opportunity, and our dinner keynote speaker Babson Professor Bob Caspe and Dr. Yingxiang Wang will share their exciting entrepreneurial stories.

Finally, our thanks go to the sponsors listed in this program, whose generosity makes this event possible. I would also like to invite you all to join and support SAPA, a non-profit organization founded in 1993. Its mission is to serve its members and to promote the pharmaceutical sciences, the biomedical and biotechnological communities, and public health interests. SAPA has more than 5,000 members in the US, and New England itself attracts more than 900 professionals. For more details, please visit our website www.SAPA-NEweb.org.

I am very excited to have you participating in our 2012 annual conference, and hope that you enjoy the keynote presentation, panel discussion, exhibition, and great networking opportunities.

Sincerely yours,

Liqiang Derek Tou, MD, PhD, MBA.
SAPA-NE 2012 Conference Chair
## Conference Program

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 – 8:50</td>
<td>Registration* and Breakfast</td>
</tr>
<tr>
<td>8:50 – 9:00</td>
<td><strong>Opening Remarks</strong></td>
</tr>
<tr>
<td></td>
<td>Liqiang Derek Tou, MD, PhD, MBA</td>
</tr>
<tr>
<td></td>
<td>SAPA-NE 14th Annual Conference Chair, SAPA-NE President-Elect</td>
</tr>
<tr>
<td>9:00 – 9:30</td>
<td><strong>Session 1: Science and Innovation in the global Market</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Drs. Liqiang Derek Tou, Xiaotian Zhong &amp; Guqing Liang</td>
</tr>
<tr>
<td>9:00 – 9:30</td>
<td>Michael Rosenblatt, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Executive Vice President and Chief Medical Officer at Merck</td>
</tr>
<tr>
<td></td>
<td>“How do We Bring the Best of Medicine to all People”</td>
</tr>
<tr>
<td>9:30 – 10:00</td>
<td>JC Gutierrez-Ramos PhD</td>
</tr>
<tr>
<td></td>
<td>SVP/CSO, Pfizer WRD</td>
</tr>
<tr>
<td></td>
<td>“Innovation and Connectivity in BioPharmaceutical Research and Development”</td>
</tr>
<tr>
<td>10:00 –10:30</td>
<td>Dr. Karin Briner PhD</td>
</tr>
<tr>
<td></td>
<td>Vice President, Head of Global Discovery Chemistry, Novartis</td>
</tr>
<tr>
<td></td>
<td>“Diverse Approaches to Drug Discovery - Keeping the Patient and Unmet Medical Need in Focus”</td>
</tr>
<tr>
<td>11:00 –12:30</td>
<td><strong>Session 2: Panel Forum I: Seizing the China opportunities in the emerging market</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr. Gaurab Bhardwaj, Jiali Chen, Jiong Jiang</td>
</tr>
<tr>
<td>11:00 –12:30</td>
<td>Panelist:</td>
</tr>
<tr>
<td></td>
<td>Ajay Sharma, PhD, MBA, Director, Business Development and Sales, Frontage Laboratories</td>
</tr>
<tr>
<td></td>
<td>Alan Wong, VP of Manufacturing Technologies, Livzon MabPharma</td>
</tr>
<tr>
<td></td>
<td>Fireli Alonso-Caplen, PhD, Senior Director of biopharmaceutical and vaccine outsourcing, Pfizer</td>
</tr>
<tr>
<td></td>
<td>George Li, MBA, Deputy CEO of Wuxi Bridgebio International Corporation.</td>
</tr>
<tr>
<td></td>
<td>Jean Qiu, PhD, Founder and President, Nexcelom Bioscience</td>
</tr>
<tr>
<td></td>
<td>Ken Li, MBA, Partner, Mingxin China Growth Fund</td>
</tr>
<tr>
<td></td>
<td>Laura Sailor, VP Sales and Marketing at Emerald Bio</td>
</tr>
<tr>
<td></td>
<td>Lisan Parker, PhD, Senior business manager, GenScript</td>
</tr>
<tr>
<td></td>
<td>Lixin Yu, Executive Director, Laviana Corporation</td>
</tr>
<tr>
<td></td>
<td>Meihan Wu, General manager of Beijing Zhongguancun Life Science Park Biomedical incubator Co., Ltd</td>
</tr>
<tr>
<td></td>
<td>Yufang Shao, PhD, Vice President, Novoprotein Scientific INC</td>
</tr>
<tr>
<td>11:00 –12:30</td>
<td>Lunch and Exhibition</td>
</tr>
</tbody>
</table>

---

SAPA-NE 14th Annual Conference 2012  
http://www.sapa-NEweb.org
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:15 – 1:45</td>
<td>Anna Protopapas, MBA, EVP, Global Business Development, Takeda Pharmaceuticals&lt;br&gt;“Takeda Pharmaceuticals: Extending their Global Reach”</td>
</tr>
<tr>
<td>1:45 – 2:15</td>
<td>Peng Wang, PhD, Vice President, Chief Scientific Officer, Simcere&lt;br&gt;“Challenges and opportunities for pharmaceutical R&amp;D in China”</td>
</tr>
<tr>
<td>2:15 – 2:45</td>
<td>Donald A. Bergstrom MD, PhD, Associate VP and Global Head, Translational and Experimental Medicine, Sanofi Oncology&lt;br&gt;“Building a global translational medicine organization: executing translational research in emerging markets”</td>
</tr>
<tr>
<td>2:45 – 3:00</td>
<td>Coffee Break and Exhibition</td>
</tr>
<tr>
<td>3:00 – 4:00</td>
<td>Zhejiang Overseas High-level Talents Exchange and Cooperation Events</td>
</tr>
</tbody>
</table>

**Session 4: Panel Forum II: Innovative drug R&D in China (Morss Hall)**

**Chair:** Mr. Xiang Niu, Dr. Gaurab Bhardwaj, Jiali Chen

<table>
<thead>
<tr>
<th>Time</th>
<th>Panelist</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 – 5:30</td>
<td>Chun-lin Chen, PhD, CEO, Medicilon&lt;br&gt;Dongxiao Feng, PhD, Executive Director, Luye Pharma&lt;br&gt;Chongqin Yi, PhD, President, PKU Care Pharmaceutical R&amp;D Center&lt;br&gt;Jason (Gang) Jin, PhD, CEO of ShanghaiBio and VP of Shanghai Biochip&lt;br&gt;Jasmine (Jisong) Cui, PhD, Chief Scientific Officer, BioDuro, PPD&lt;br&gt;Lianshan Zhang, PhD, President of Global R&amp;D, Jiangsu Hengrui&lt;br&gt;Patrick Y. Lu, PhD, President &amp; CEO, Sirnaomics&lt;br&gt;Steve Sun, PhD, Chairman and CEO of GENEWIZ Inc.&lt;br&gt;Yinxiang Wang, PhD, CEO&amp;CSO, Zhejiang Beta Pharma Inc.</td>
</tr>
</tbody>
</table>

**SAPA-NE 14th Annual Conference Dinner Reception (ticket required)**

**Chair:** Liqiang Derek Tou, Huo Li, Jie Zhao

<table>
<thead>
<tr>
<th>Time</th>
<th>Place: MIT Faculty Club</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 – 9:30</td>
<td>Open Bar and Networking&lt;br&gt;Welcome Remarks: Min Chen, PhD, SAPA-NE President/ Leland Cheng, Cambridge Councilor / Zhejiang governor/ Zhejiang Future Industry Park&lt;br&gt;Plate Dinner&lt;br&gt;SAPA-NE Service Award Presentation&lt;br&gt;High School Excellence Scholarship Award Presentation&lt;br&gt;Dinner Keynote: Bob Caspe Founder, International Entrepreneurship Center, Professor at Babson College&lt;br&gt;Yinxiang Wang, PhD, CEO&amp;CSO, Zhejiang Beta Pharma Inc.</td>
</tr>
</tbody>
</table>
About the Speakers

Session 1: Science and Innovation in the global Market

Dr. Michael Rosenblatt, MD, PhD
Executive Vice President and Chief Medical Officer, Merck

Scientist, educator, hospital and global healthcare company executive, Michael Rosenblatt, M.D., is Executive Vice President and Chief Medical Officer at Merck. He represents the voice of the patient and medicine inside Merck and is the company’s primary external advocate on medical issues.

Dr. Rosenblatt previously was Dean of Tufts University School of Medicine and the George R. Minot Professor of Medicine at Harvard Medical School. He served as the President of Beth Israel Deaconess Medical Center. He was also Director of the Harvard-MIT Division of Health Sciences and Technology.

Prior to these leadership positions, he was Senior Vice President for Research at Merck where he co-led the worldwide development team for alendronate (FOSAMAX®), Merck’s bisphosphonate for osteoporosis and bone disorders. From 1981 to 1984, he served as Chief of the Endocrine Unit at the Massachusetts General Hospital.

He is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck.

Committed to innovation, he has served on the board of directors and scientific advisory boards of several biotechnology companies. Dr. Rosenblatt was elected to the American Society of Clinical Investigation and the Association of American Physicians, is a fellow of the American Association for the Advancement of Science and the American College of Physicians, and served as the president of the American Society of Bone and Mineral Research.

He has served as a consultant to the U.S. President's Council of Advisors on Science and Technology.

He received his undergraduate degree summa cum laude from Columbia University and his M.D. magna cum laude from Harvard Medical School. He trained in internal medicine and endocrinology at the Massachusetts General Hospital.

“How do We Bring the Best of Medicine to all People”

The biopharmaceutical industry is the most research-intensive industry in the world, routinely investing 20 percent or more of revenues in R&D. But scientific innovation is an increasing struggle – technically, economically and even emotionally. How can we sustain today’s quality of innovation despite the growing challenges? Dr. Michael Rosenblatt, Executive Vice President and Chief Medical Officer, Merck, will discuss developments on the new frontier of innovation — collaboration. Whether inside the research laboratory or on the front lines with patients in local communities, novel models for collaboration are needed to help address the world’s most pressing health needs. Dr. Rosenblatt will explore new kinds of alliances that are helping to fuel health innovation. He will explore examples ranging from research institutes and venture funds to pre-competitive technology alliances to partnerships involving different companies and multiple sectors – all of which underscore the value of collaboration.
Session 1: Science and Innovation in the global Market

JC Gutierrez-Ramos PhD
Senior Vice President, Head of BioTherapeutics Research & Development Pfizer Inc

Jose-Carlos “JC” Gutierrez-Ramos, PhD, is Senior Vice President and Head of BioTherapeutics Research & Development, within Pfizer Worldwide Research & Development. JC is passionate about the early and iterative use of experimental medicine approaches in discovery research, the continuous focus on scientific innovation and medical differentiation during drug discovery, and the “entrepreneurialization” of big pharma research groups.

Prior to joining Pfizer, JC was Senior Vice President and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at Glaxo Smith Kline. JC built the iiCEDD as a global group of “drug hunters” that included biologists, chemists, pharmacologists, protein scientists, clinicians and business developers who were responsible for drug discovery and development through Phase IIa (Proof of Concept). Chief achievements in the formation of the iiCEDD included entrepreneurial organizational and funding structure, the talent recruitment and identification of innovative discovery areas to focus on, which were poised for medical differentiation. The iiCEDD pipeline had a significant external component with 50 percent of its pipeline and activities achieved through external partnerships with biotech companies, academia and contract research organizations.

Prior to GSK Jose-Carlos served as Site Head and Chief Scientific Officer (CSO) at AMGEN Mountain View. Previous to the AMGEN acquisition of Avidia, he was the Senior Vice President of R&D, where he led a significant effort of novel protein therapeutics for autoimmune disease. Before his AVIDIA appointment, he served as CSO of Peptimmune Inc. in Cambridge, MA, where he was responsible for the development of peptide based therapeutics for autoimmune disease, including multiple sclerosis and diabetes. Before Peptimmune, JC served as Vice President, Inflammation at Millennium Pharmaceuticals, where he was responsible for advancing preclinical candidates in Inflammation & Immunology to human trials and advancing compounds (small molecules and antibodies) from discovery through clinical development.

“Innovation and Connectivity in BioPharmaceutical Research and Development”
Session 1: Science and Innovation in the global Market

Karin Briner, PhD
Vice President, Global Head of Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge

Dr. Briner obtained her BSc in Chemistry and Biochemistry and her PhD in Organic Chemistry from the University of Zurich. She did NSF and NIH postdoctoral studies at Indiana University. In 1995, she joined Eli Lilly & Co. in Indianapolis as Senior Organic Chemist and became soon thereafter a project leader in the Neuroscience Research area.

From 2000 to 2010, she was a member of the Discovery Chemistry management team with increasing responsibilities, starting as Medicinal Chemistry Director in Neuroscience and Endocrine Research, later as Executive Director for Global Lead Optimization Chemistry and for Discovery Chemistry at the Lilly European Sites. Throughout this time up to 2007, she maintained her own research laboratory contributing new portfolio projects and delivering molecules into the clinic.

From 2007 to 2010, she was Managing Director and Research Head of the Lilly Research Centre, UK, with a focus in Neuroscience Research.

In 2010, she became Vice President of Translational Sciences and Technologies, located in Indianapolis, with responsibilities for biomarker discovery research across all therapeutic areas, centralized in vitro screening, and structural biology.

In June 2011, Karin joined Novartis as Global Head of Discovery Chemistry.

“Drug Discovery Challenges and Opportunities – Keeping the Focus on the Patient and Unmet Medical Need”

An overview of some challenges in drug discovery and our attempts to address them will be given.

Some specific projects will be discussed, highlighting the exciting opportunities created through science and technology innovations guided by patient needs.
Session 3: Business Development in the Emerging Market

Anna Protopapas, MBA
EVP, Global Business Development Takeda Pharmaceuticals

Anna Protopapas is the Executive Vice President of Global Business Development at Takeda Pharmaceuticals responsible for licensing, acquisitions, alliance and licensee management as well as venture investing. She is a member of Takeda’s executive team and a corporate officer. Since assuming the role, she has helped build Takeda’s global capabilities in business development and led the strategic initiative that resulted in the 9.6 billion euro acquisition of Nycomed, a transaction that transformed Takeda into a top pharmaceutical company with a global footprint.

Prior to assuming this role, she was responsible for leading the strategy and business development effort at Millennium Pharmaceuticals were she was instrumental at driving various strategic transactions that transformed the company from an early stage technology company to a fully integrated oncology leader. She led the partnership discussions with Takeda Pharmaceuticals that ultimately resulted in the acquisition of Millennium by Takeda for $8.8 billion. Following the acquisition, she led the successful integration between the two companies that established Millennium as Takeda’s oncology center of excellence.

Prior to Millennium, Anna held various positions outside the life science industry in engineering, global marketing and business development. She holds a BSE in Chemical Engineering from Princeton University, Masters in Engineering from the Massachusetts Institute of Technology and an MBA from the Stanford Business School. She is a native of Cyprus and now lives in Boston with her husband and three children.

“Takeda Pharmaceuticals: Extending their Global Reach”

Takeda Pharmaceuticals, Japan’s leading pharmaceutical company, has a long history of bringing innovative medicines to patients around the world. The company is accelerating its growth to increase its presence in new and emerging markets, and become a leading global pharmaceutical player. In recent years Takeda has acquired Millennium Pharmaceuticals which helped them strengthen their presence in the all-important oncology market, and Nycomed which helped Takeda gain access to many emerging markets. Currently the company spans across five geographies and over 70 global markets. Takeda has had a long standing commitment to bringing innovative products to the Chinese market. That effort has been strengthen through the acquisition of Nycomed and through continued investment by Takeda to continue to build capabilities and fuel growth. During her presentation, Ms. Protopapas will provide an overview of Takeda’s global business development strategy, while offering an insight into the opportunities presented in China.
Session 3: Business Development in the Emerging Market

Peng Wang, PhD
Vice President, Chief Scientific Officer
Simcere

Dr. Peng Wang, a member of the China National “1000-Talents Program”, is currently Chief Scientific Officer of Simcere Pharmaceuticals Group, a leading Chinese pharmaceutical company headquartered in Nanjing, China (simcere.com; “SCR” at NYSE). Prior to joining Simcere, Dr. Wang was with WuXi PharmaTech (wuxiapptec.com; “WX” at NYSE), a leading pharmaceutical CRO in China, as Vice President of Discovery Biology in 2008-2009. Prior to joining WuXi PharmaTech, Dr. Wang worked on discovery through early clinical development for Schering-Plough in New Jersey, USA for 18 years. Dr. Wang has made significant contributions to discovery and early development of 16 drug candidates in US and China, and to establishment of several collaboration partnerships between Simcere and US companies. Dr. Wang has published numerous papers as corresponding author in leading scientific journals such as Proc. Natl. Acad. Sci. USA, J. Biol. Chem., Blood, J. Immunol., Am. J. Respir. Crit. Care Med., Mol. Pharmacol., Biochem. J. etc. Dr. Wang received his PhD in Biochemistry from the University of Tokyo, and his B.S. in Medicinal Chemistry from the China Pharmaceutical University.

Challenges and opportunities for pharmaceutical R&D in China

Although in US/Europe the industry R&D expenditures have now flattened, in China the R&D boom is just starting. There are unique challenges and opportunities for R&D in China, which will be discussed in this presentation. In addition, our new approaches aimed at improving R&D productivity will be discussed as well.
Donald A. Bergstrom MD PhD  
Associate VP and Global Head,  
Translational and Experimental Medicine  
Sanofi Oncology

Donald Bergstrom joined Sanofi Oncology in May 2010 as Associate Vice President and Global Head of Translational and Experimental Medicine, where he leads a team of laboratory and clinical scientists who integrate translational science into oncology drug development to ultimately improve the care of patients with cancer. The group is dedicated to molecular understanding of pre-clinical models on which decisions to pursue clinical development are based, and then designing clinical research strategies to most closely mimic the successful pre-clinical program. Prior to joining Sanofi, Bergstrom spent 6 years at Merck Research labs where he held roles of increasing responsibility in the Clinical Molecular Profiling, Oncology Clinical Research and Experimental Medicine Oncology groups. Prior to joining industry he completed his MD degree at the University of Washington and his PhD and post-doctoral training at the Fred Hutchinson Cancer Research Center, both in Seattle, WA. He was a resident in Clinical Pathology at the University of Washington.

**“Building a global translational medicine organization: executing translational research in emerging markets”**

Novel clinical trial endpoints, including molecular imaging and genomics, hold great promise for the development or more effective cancer drugs. Traditionally these studies have been confined to either early phase clinical trials or translational sub-studies embedded into global late phase trials. In either case global pharmaceutical companies have typically only pursued these complex studies at a relatively small number of well-established academic medical centers, predominantly in North America and Western Europe. As global pharmaceutical companies increase their focus on emerging markets for the development of both global and regional products, they have had to focus on building global translational medicine capabilities. This talk will present one approach to building such an organization, pairing global subject matter expertise within the pharmaceutical company with external capabilities within the emerging market.
Session 2: Panel Forum I: Seizing the China Opportunities in the Emerging Market

Gaurab Bhardwaj, PhD, Endowed Chair Professor, Babson College

Gaurab is the faculty director of Babson’s executive education program “Bio-Pharma: Mastering the Business of Science” for biopharma scientists and managers. In addition to teaching competition and strategy in this program, he teaches in the MBA program and has taught in custom programs for Eli Lilly, Biogen Idec, Dana Farber Cancer Institute, EMC, and Lucent Technologies. Gaurab has a PhD in strategy and management from the University of Pittsburgh and an MBA from Northeastern University.

Associate Professor and The Louis J. Lavigne, Jr. Family Endowed Term Chair in Strategy & Planning Faculty Director, BioPharma Program, Babson Executive Education Babson College, Wellesley, MA.

Gaurab’s research, teaching, facilitation, speaking, and consulting expertise are in strategy, innovation, and entrepreneurship in science-based companies, especially those in biotechnology, pharmaceuticals, medical devices and diagnostics, agriculture, healthcare, and chemicals. The National Science Foundation and the Eleutherian Mills – Hagley Foundation have funded his on-going research program on the “Management of Distant Returns” where he is investigating how people make decisions that are highly uncertain and ambiguous, and whose outcomes take shape over many years. His research, writing, and professional presentations are on discovery processes of corporate scientists, science and strategy for achieving long-term corporate growth, and anticipatory innovation and entrepreneurship. His work has involved scientists and managers in pharmaceutical, agriculture, and biotechnology businesses. He is currently working, along with the founder of a biotechnology company, on a new way to innovate that anticipates markets.

Ajay Sharma, PhD, MBA, Director, Business Development and Sales, Frontage Laboratories

Dr. Ajay Sharma is the Director of Business Development and Sales for Frontage, a global pharmaceutical research and development company with GMP labs and clinical research facilities in the U.S. and China. Frontage provides a broad range of drug development services for pharmaceutical discovery, development, preclinical, clinical research, and regulatory consulting.

Dr. Sharma obtained his PhD in Molecular Biology from University of Southern California and an MBA from Rutgers University, NJ. Dr. Sharma has over 20 years of R&D, Management and Business Development experience in the broad life sciences industry including Drug Discovery and Development. He is experienced in product positioning for commercialization, strategic planning, product development, process improvement, and technology evaluation. Prior to joining Frontage, Dr. Sharma held a variety of Dr. Sharma held a variety of management positions in pharmaceutical and service companies, including Associate Director, Business Development at Caliper Life Sciences; Director...

Gaurab’s research has been published in the journals Management Science, Expert Opinion on Drug Discovery, Chemical Heritage, and as a chapter in the book Innovating Strategy Process. He has written for BioExecutive International and Babson Insight and his work has been covered in Effective Executive.
R&D, Molecular Biology at Millipore Corp.; and Director, R&D at Bionaut Pharmaceuticals. As a senior scientist at Baxter International (Nextran Inc) Dr. Sharma worked on a Human Blood substitute and conducted research in the field of Xenotransplantation.

Dr. Sharma holds multiple US patents and publications in molecular and cellular biology, oncology, transgenics, glycosylation, protein expression and immunology.

Alan Wong, VP of Manufacturing Technologies, Livzon MabPharma

Alan has a MBA in Finance (Le Moyne College) and a BS in Chemical Engineering (University of Rochester). He has Over 23 years' experience in biopharmaceutical industry with extensive experience in clinical/commercial manufacturing, external manufacturing, global supply chain, cold chain management, project management, strategy development, strategic/financial analysis, start up, scale up, process design/development, technology transfer and technology implementation. Experience also includes, but is not limited to, international operations, virtual operations, coaching and training. Biopharmaceutical companies Alan has worked for include Livzon MabPharm, Inc., Regeneron, Biogen-Idec, Wyeth (Pfizer), Millennium, Bristol-Myer Squibb, Schering-Plough (Merck) and Genex. Accomplishments achieved include, but not limited to, helping design a 170,000 sq ft antibody facility for GMP manufacturing, improving production yields, streamlining processes, improving operations efficiency, improving strategic partners’ working relationship, cost-saving for companies ranging from $50,000 – over $1 million annually.

Firelli Alonso-Caplen, PhD, Senior Director of biopharmaceutical and vaccine outsourcing, Pfizer

Dr. Firelli Alonso-Caplen is a Senior Director at Pfizer, Inc. She heads the Biotherapeutics and Vaccines Outsourcing group within the BioTherapeutics Pharmaceutical Sciences organization of Worldwide Research and Development. Fi has more than 27 years of combined experience in research, development, and cGMP production of biological products and vaccines, and more than 7 years experience in outsourcing, project / contract management, and technology transfer to qualified third parties. Her areas of expertise include viral vectors and vaccine development, biotherapeutics and vaccine process development and cGMP production, project management, technology transfer, outsourcing, and budget and operations.

She obtained her PhD in Microbiology from the University of Alabama in Birmingham, followed by postdoctoral research at the U.S. Army Medical Research Institute for Infectious Diseases, Sloan-Kettering Institute for Cancer Research, and Rutgers University Center for Advanced Biotechnology and Medicine. Prior to working for Wyeth / Pfizer in 1996, Fi was at The Salk Institute (Government Services Division), a vaccine contract manufacturer for the U.S. Army.

George Li, MBA, Deputy CEO of Wuxi Bridgebio International Corporation.

Mr. Li has over 20 years experience of R&D, management and start-up in high technology industry. As one of the founding member of BridgeBio, in 2008 he took position of vice president and led company’s responsibilities of strategic planning, project recruiting and investment. In 2011, he has been named as CEO of
Wuhan Bridgebio Park which has strategic collaboration with Wuhan Biolake. Previously, he has involved in other two start-ups and participated the company set up, joint venture, US operation, venture financing and exit. Mr. Li started his career as engineer, project manager, department manager in Huawei and led R&D team to launch its first wireless communication system in China. Mr. Li got his MBA from Hult International Business Scholl and bachelor degree from Zhejiang University.

Jean Qiu, PhD Founder and President, Nexcelom Bioscience

Dr. Jean Qiu is the founder and President of Nexcelom Bioscience LLC. From the basement of her home, she started the company in 2003, with the goal of automating manual cell counting and analysis on the biologist’s lab bench. Today, the Cellometer-branded cell counting systems, consisting of instrument, software and consumables, are distributed globally and used in laboratories of pharmaceutical companies, government institutions and universities for biomedical research, such as cancer research, vaccine development and drug discovery. The company has now grown to nearly 30 people in Lawrence, Massachusetts, where the dedicated entrepreneurial team covers everything from engineering and manufacturing to marketing and customer service.

Prior to Nexcelom Bioscience, Dr. Qiu worked for 3M Company for more than a decade, as a product commercialization team leader in Health Care Group, Research Specialist in the Material Application Laboratory, and Senior Research Engineer in the Corporate Research Laboratory, where she was a co-inventor of the first blue-green semiconductor laser. She also worked for a biotech start-up, as its Director of Process Development and Manufacturing, where she developed plastic optical sensors and established its manufacturing process.

Dr. Qiu earned her PhD in Electrical Engineering from Purdue University in 1990 and her BS is Electrical Engineering from Nanjing Institute of Technology in China. She has published numerous papers in peer-reviewed academic journals and holds 23 US patents. Awards received include the Rank Prize for Opto-Electronics, London, UK, 1993, for the invention of the blue-green diode laser, and 3M Company’s Excellent Record of Invention Award. In 2006, Dr. Qiu was honored by the Boston Woman’s Business Journal with the Hall of Fame Award.

Ken Li, MBA, Partner at Mingxin China Growth Fund

Ken has over 20 years experience on the drug R&D, kilo lab, pilot plant, cGMP, management fund raising, investment, startup in the US and China. Ken is now partner of Mingxin China Growth Fund focusing on the life science investment. Ken was CEO of Beijing KYY Biosciences. Prior that, Ken was general manager of Chiral Quest Inc. (China), he led the China operation and raised a total of $18m and 120yuan to build up the Suzhou pilot plant and production facility. He worked for Eisai Research Institute as Senior chemist and worked for Wyeth as Chemist. He was founder of SAPA-NE. Ken is evaluator for some China state key projects and served as advisor for some companies. He received MBA from Babson and master degree from City College of New York.

Lisan Parker, PhD, Senior business manager, GenScript

Prior to joining GenScript, Lisan was Research Liaison at Johns Hopkins University for the TB Research Center. Her efforts supported the establishment of the Kwa-Zulu Natal Research Institute for TB and HIV, a Howard Hughes Medical Institute sponsored initiative. She became involved in TB drug research and development as Scientific Liaison to the TB Alliance (a non-profit TB drug development company) and the World Health Organization Working Group on New Drugs.

Lisan’s drug discovery experience stems from her time at Merck Research Laboratories as a Senior Research Biologist in Neuroscience Drug Discovery. While at Merck, she established productive external academic collaborations as well as an internal cross-site collaboration that supported key projects. These examples demonstrated her managerial skills, strong cross functional abilities, and ability to produce results that demonstrate impact. She also coordinated and managed the research activities of a biology team for a drug discovery program while at Merck.

Lisan completed her PhD in Pharmacology at Vanderbilt University, followed by postdoctoral training in Developmental Neurobiology at St. Jude Children’s Research Hospital.

With 15 years experience in pharmaceutical industry, he has built strong skill in drug development, management of research team, implement of GMP in production, and compliance of both FDA and SFDA regulation.

1989, Lixin was graduated from Beijing University with a B.S. degree. He earned his Master degree in Analytical Chemistry from Southern Illinois University at Carbondale in 1996.

Meihan Wu, General Manager of Beijing Zhongguancun Life Science Park Bio-medical incubator Co., Ltd

Ms Wu was graduated from the Second Military Medical University, and now is the general manager of Beijing Zhongguancun Life Science Park Bio-medical incubator Co., Ltd. Ms. Wu has worked for the Institute for Drug and Instrument Control of Health Dept of the General Logistics Department (GLD) of the Chinese People's Liberation Army (PLA) as associate superintendent, the medicine inspection office of Health Dept in GLD of PLA as director, and Shanghai Qingan Pharmaceutical Group as vice-general manager and CTO.

Yufang Shao, PhD, Vice President, Novoprotein Scientific INC

Dr. Yufang Shao received a B.S. from Fudan University in 1996 and PhD in Neurobiology from SUNY at Stony Brook in 2002. She completed her postdoctoral training in the field of programmed cell death at the Memorial Sloan Kettering Cancer Center in New York City and was promoted to Senior Scientist working on novel drug screening at the same institute. In 2009, Dr. Shao was recruited to Hoffman-La Roche pharmaceuticals as Principal Scientist.

Since 2011, Dr. Shao joined Novoprotein Scientific as Vice President in charge of its global marketing.
Session 4: Panel Forum II: Innovative Drug R&D in China

Chun-lin Chen, PhD, CEO, Medicilon

Chun-Lin Chen got B.S. and M.S. from China Pharmaceutical University in 1983 and 1986. During 1986-1991, Chun-Lin Chen worked as an Assistant Professor in China Pharmaceutical University. In 1994, Dr. Chen got PhD in Pharmacology and Toxicology from Oklahoma State University and then he got postdoctoral training in Pharmaceutical Department of St. Jude Children’s Research Hospital. During 1997-2002, Dr. Chen served as a Director of Pharmaceutical Department at Parker Hughes Cancer Center, Parker Hughes Institute, St. Paul, USA. In 2002, Dr. Chen joined Vertex Pharmaceuticals as a Staff Investigator at Department of Pharmacokinetics and Metabolism, Non-clinical Drug Evaluation Division, Vertex Pharmaceuticals Incorporated, Cambridge, USA. He managed pre-clinical drug evaluation team and lead to three IND filing approved by FDA. Dr. Chen is a founder of Medicilon Inc. Dr. Chen has over 80 publications in the field of drug discovery and drug development. Dr. Chen got several awards including Excellent Teacher Award from China Pharmaceutical University, Research Excellent Award from Oklahoma State University, and Excellent Returnee Award from Shanghai and “1000-talent Program” award from Chinese government. Dr. Chen currently serves as Associate Director for Drug Metabolism Section of Shanghai Pharmacology Society, Board Member for Pudong Biopharmaceutical Association. He was a member for American Association of Pharmaceutical Scientists, International Society for the Studies on Xenobiotics, Society of Chinese Bioscientists in America, American Society for Pharmacology and Experimental Therapeutics, American Association for the Advancement of Science and American Society of Toxicology.

Dongxiao Feng, PhD, Executive Director, Luye Pharma

Dr. Feng is currently an Executive Director at Luye Pharma. His research interests include transgenic animals, antibody engineering, humanized antibodies, humanized monoclonal antibody drugs. In the past decade, Dr. Feng has carried out researches on bacterial artificial chromosome mediated transgenic animal, humanized monoclonal antibody via transgenic animal technology and Phage display, humanized transgenic mice, etc... He has discovered many kinds of human monoclonal antibodies and humanized murine antibodies targeting at viruses, cancer cells, and autoimmune system. He has more than 10 publications on international leading journals and attended many international conferences. Dr. Feng received his B.S. in Biochemistry from Shandong University, a M.S. in immunology from Academy of Military Medical Sciences and obtained a PhD in Molecular Biology and Biochemistry from Chinese Academy of Medical Sciences.

Chongqin Yi, PhD, President, PKU Care Pharmaceutical R&D Center

Dr. Yi is currently Vice President of PKU International Healthcare Group and President of PKU Care Pharmaceutical R&D Center. Dr. Yi got her B.S. from Sichuan Continuing Education College of Medical Sciences in 1990 and M.S. from Beijing Traditional Chinese Medicine Research Institute in 1993. She got her PhD in Biochemical Pharmacology of Integrative Medicine from Beijing University of Chinese Medicine in 1997, and from 1997 to 1999
she did postdoctoral training in the Post-doctoral Research Station of Guang’anmen Hospital of Chinese Academy of Chinese Medical Sciences. During 1999-2000, Dr. Yi was a visiting scholar at Pharmacology and Toxicology Research Institute of Freie in University of Berlin. From 1999-2007, she was a Director and later on promoted to Deputy General Manager at Chongqing Taiji Industry (Group) Co., Ltd. Dr. Yi was awarded Beijing Science and Technology Progress Prize in 1994, 3rd class. She also involves as committee members in several professional associations.

**Jason (Gang) Jin, PhD, CEO of ShanghaiBio and VP of Shanghai Biochip**

Dr. Jason (Gang) Jin is the Co-Founder and CEO of ShanghaiBio Corporation (SBC for global CRO at US), and Co-Founder and Executive VP for Global Business of Shanghai Biochip Co. Ltd (SBC in China), a leading biotech in China with lab operations at Shanghai and global business office at New Jersey in U.S. Dr. Jin is also an adjunct professor at the Shanghai Institutes of Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), and School of Pharmacy, Fudan University. Dr. Jin has extensive scientific and management experience in drug discovery and development. He has successfully developed and managed over 100 collaborative projects in genomics, pharmacogenomics, biomarker, translational medicine, companion diagnostics to support discovery, pre-clinical research, and clinical trials with top global pharmaceutical and biotech companies in the past six years. He was awarded as one of top 10 American-Chinese returnees by Business Week in 2008. Dr. Jin also got the top 10 American-Chinese Business Award in 2010 at US. Dr. Jin has held the former positions of Director of Genomics Lab at Purdue Pharma (USA), Director of Functional Genomics at Salk Institute (USA), Founder Director of National Engineering Center for Biochip at Shanghai (China), and radiologist at Shanghai Zhongshan Hospital (China). He received PhD and Postdoctoral Fellow in biology from University of California, San Diego (USA), and medical degree from School of Medicine, Fudan University (Shanghai Medical University, China). Dr. Jin also attended the intensive MBA class in Rutgers University.

**Jasmine (Jisong) Cui, PhD, Chief Scientific Officer (CSO), BioDuro, a PPD Company**

Dr. Cui is the CSO of BioDuro since August of 2011. Her areas of responsibility include BioDuro’s overall scientific and operational management, as well as business & resource management. Dr. Cui has 16 years of drug discovery and development experience. She has broad knowledge across variety of therapeutic areas and advanced experience in leading early phase drug development programs. She also has experience in translational medicine and depth of knowledge on the entire drug R&D process. Prior to joining BioDuro, Dr. Cui had a productive career at Merck Research Laboratories in Rahway, New Jersey. She had worked at Merck for 14 years with increasing responsibilities. She was the Director of Cardiovascular Diseases at Merck from 2007-2010. Dr. Cui had led teams working on drug discovery programs in multiple therapeutic areas including endocrinology, respiratory diseases, metabolic disorders, cardiovascular diseases and hypertension and had identified several preclinical drug candidates. Additionally, Dr. Cui had served as Vice President and Head of Drug Discovery and Translation at Hua Medicine responsible for the company's program portfolio and execution of programs in preclinical space to Phase IIa. She is an author/inventor on over 80 publications / patent applications / meeting abstracts and an invited speaker for numerous international conferences / forums.

Dr. Cui served as the SAPA President of 2009-2010, the first female President in the 18 year's history of this organization. She has led numerous SAPA committees and organized many SAPA conferences and other events. She has received several prestigious awards in New Jersey and Chinese American society for her excellent service to communities through her
leadership to SAPA.
Dr. Cui received her B.S. in Biology from Shandong University, obtained a PhD in Molecular Biology and Biochemistry from Purdue University and conducted post-doctoral training at the Howard Hughes Medical Institute affiliated to the University of Michigan Medical School.

Lianshan Zhang, PhD, President of Global R&D, Jiangsu Hengrui

Dr. Lianshan Zhang is currently the President of Global R&D at Jiangsu Hengrui Medicine, a leading Chinese pharmaceutical company with top market share in oncology drug sales in China. Hengrui is widely recognized as the domestic leader in pharmaceutical R&D innovation. In 2010, Dr. Zhang joined Hengrui and takes the responsibility for R&D strategy and management of dozens of NME or reformulation programs at research sites across the globe. Prior to Hengrui, he was a senior research executive at Marcadia Biotech, in charge of all the chemistry efforts and external research collaborations. Due to the success of its development programs, Marcadia was acquired by Roche for over $287 million in December 2010. From 1998 to 2008, Dr. Zhang served as a senior scientist with Eli Lilly and Co. where he was engaged in the discovery and development of peptide therapeutics for the treatment of diabetes and obesity.
Dr. Lianshan Zhang obtained his undergraduate degree in Medicinal Chemistry from China Pharmaceutical University and his PhD (summa cum laude) in Organic Chemistry under the supervision of Professor Ernst Bayer at the University of Tubibgen.

Patrick Y. Lu, PhD, President & CEO, Sirnaomics

Dr. Lu is the founder and President/CEO of Sirnaomics, Inc., (since 2007) and Chairman/CSO of Suzhou Sirnaomics Pharmaceuticals, Ltd., in Biobay, SIP, China. Dr. Lu started his biopharmaceutical industry career in 1993 and severed as a lab head and senior scientist in Novartis and Digene (Until 2000). Dr. Lu was the co-founder and Executive Vice President of Intradigm Corporation (2001-2006). Patrick has authored more than 50 scientific papers, review articles and book chapters, and holds 32 issued and pending international patents. He has been an invited speaker in many international conferences throughout the world. Dr. Lu has been awarded a number of grants from NIH (2008-2010) and local governments. Under his leadership, Sirnaomics has developed novel siRNA therapeutic programs and established partnerships with Chinese Pharmaceutical companies and US biotech companies. In China, Patrick has received multiple awards for his entrepreneurial successes and served as the PI for several government grants for innovative pharmaceuticals. Dr. Lu received his PhD from Sun Yatsen University in China (1987) and completed has postdoctoral training in University of Maryland and Georgetown University (1992).

Steve Sun, PhD, Chairman and CEO of GENEWIZ Inc.

Dr. Sun is the Chairman and CEO of GENEWIZ, Inc., the company he co-founded in 1999. Dr. Sun received the Ernst & Young 2010 Entrepreneur of the Year Award in New Jersey. The Ernst & Young award recognizes outstanding entrepreneurs who are building and leading dynamic and growing businesses. Dr. Sun serves as a member of the Scientific Advisory Board at Neogenix Oncology Inc, a cancer therapeutics and diagnostics company with operations in the states of New York and Maryland. Dr. Sun has been serving as a member of the Board of Directors at Frontage Laboratories since its founding in 2000. Frontage specializes in pharmaceutical analysis, bio analytical testing and method development, and custom synthesis of investigational compounds, with operations in the U. S. and China. Dr. Sun serves as a member of the Innovation Sounding Board of Rutgers University's Center for Innovative Ventures of Emerging Technologies (CIVET). CIVET's mission is to encourage
dialogue between academic researchers, their industrial counterparts, and entrepreneurs regarding technology commercialization. Dr. Sun serves as a member of the Advisory Board of the Commercialization Center of Innovative Technology (CCIT), a New Jersey Economic Development Authority (NJEDA) organization.

Dr. Sun obtained his Bachelor and Master degrees from Tsinghua University in Beijing. He obtained his PhD from Columbia University in the City of New York. Dr. Sun received his postdoctoral training at The Rockefeller University. Starting GENEWIZ, Inc. is his first job.
SAPA-NE 14th Annual Conference Dinner Keynote Lecture

Bob Caspe, Founder, International Entrepreneurship Center, Professor at Babson College

Currently, I'm teaching "Marketing for Entrepreneurs" at Babson's MBA Graduate Entrepreneurship program and I am doing some consulting for small high-tech startups.

I've started 3 high-tech companies. The first was in the medical instrumentation business where we built array processors and nuclear medicine systems. The second, Leaf Systems, Inc. was in the newspaper imaging business and also built one of the world's first digital cameras for professional use. My third company was in the consumer imaging business where we sold a variety of digital cameras and accessories through retail channels and through infomercial direct marketing.

Therefore, I've been exposed to a variety of B2B and B2C marketing channels. As well I understand how to source product in Asia. I am familiar with many of the issues that challenge small companies.

For a more complete resume, go to http://www.caspegroup.com

Specialties

product design, software design, medical instrumentation, imaging products, audio products, signal processing, marketing, direct marketing, small business growth.

“Evolution and technology and the impact on the entrepreneur”

Intro to the IEC The International Entrepreneurship Center (IEC) is a startup-incubator or hatchery located in Newton Massachusetts at 320 Nevada Street. It was started by a team of experienced entrepreneurs and teachers who believe that there are essential missing pieces at other startup hatcheries. First, we offer mentorship to our member companies. Sometimes it's assistance with strategy but more often it's help with important tactical steps like closing the first sale, or meeting potential customers. We endorse business models that can be “customer financed” as opposed to venture financed and we discourage the writing of business plans and attempt to raise funds before the first transaction with a real customer is completed. Second, we offer entrepreneurship education. We have several teachers on staff who teach part time at prestigious business schools both undergraduate and graduate programs and we have tailored a set of seminars to the needs of the startup. We offer these courses to our hatchery members, and we also teach throughout the world at universities, and hatcheries in other countries. Finally, we are a network of interconnected hatcheries who facilitate the movement of business models to other regions as an alternative to building an international company. Our website is at http://iecpartners.com

We believe in “Knowledge capital in place of Venture capital.”
Yinxiang Wang, PhD, CEO&CSO, Zhejiang Beta Pharma Inc.

Dr. Yinxiang Wang is the CEO and Chief Scientist Officer (CSO) of Zhejiang Beta Pharma, Inc. (ZBPI). He is also a member of the Chinese Program of Global Experts (also known as the “1000 Plan”). In his current position, Dr. Wang, is instrumental in the research and development of a great number of new drugs for oncology and diabetes.

As the CSO and one of the main innovators at ZBPI, Dr. Wang headed the research team which developed Icotinib Hydrochloride (Conmana®), a National Category-1 Novel Drug (NME). He was the project leader in charge of the pre-clinical and clinical phase I-III studies of Icotinib Hydrochloride as well as the commercialization of Icotinib. This novel drug is the first small molecule oncology drug specifically targeting cancer cells that is completely developed in China. Its chemical structure has already been patented in both China and US, whereas patent application worldwide is currently underway. ZBPI successfully obtained approval on Icotinib Hydrochloride from Center for Drug Evaluation at SFDA at the end of 2010 and started marketing Conmana® in 2011.

Dr. Wang is also one of the founders of ZBPI New Drug Research Center in Beijing, established in 2003. Currently, he is leading the scientists at the center in researching and developing pipeline drugs, out of which two NME drug are going to be IND application and five generic products (including 2 drugs that are the first market approval in China) have already been approved and commercialized. In 2010, Eli Lilly invested in and formed a strategic alliance with ZBPI that marked the beginning of new collaboration efforts to develop future products and technologies.

Beta Pharma (China)’s ten years in China

贝达药业的十年
2012 SAPA-NE Outstanding Corporate Award Winners

MERCK & CO., INC.
Whitehouse Station, N.J., U.S.A.

NOVARTIS
NOVARTIS INSTITUTES
FOR BIOMEDICAL RESEARCH

Takeda
MILLENIUM
THE TAKEDA ONCOLOGY COMPANY

Simgere

Z-Park
ZHONGGUANDUN SCIENCE PARK

SAPA-NE 14th Annual Conference 2012
http://www.sapa-NEweb.org
2012 SAPA-NE Service Excellence Award

Dr. Qingcong Lin  
Dr. Long Jiang  
Dr. Jie Zhao  

Dr. Dapeng Chen  
Dr. Quiqing Liang
2012 SAPA-NE High School Excellence Scholarship

SAPA-New England Chapter (SAPA-NE,) established and conducted the first SAPA-NE High School Excellence Scholarship in 2008. This program is a merit-based award to graduating high school seniors who have demonstrated excellent academic performance and leadership and will pursue first undergraduate degree at U.S. accredited institutions. As a professional organization, SAPA-NE encourages the candidates’ interest and dedication toward a career in life science/heath care. Two outstanding high school students were selected out of a competitive candidate pool to be the winners of 2009 SAPA-NE High School Excellence Scholarship.

Iris Zhou

- Cumulative GPA: 4.90, Total SAT Scores: 2390
- State Top Scorer in Academic Decathlon
- Summa Cum Laude in National Lain Exam
- Founder and President of the New England Youth Performing Group
- Volunteer with “Walk for Hunger” for 5 years

Iris is graduating from Wellesley High School. Her excellent academic performance was testified full score of 1600 on SAT (800 on both verbal and math). She grew up in a family with traditional Chinese medicine practice which allowed her understanding and appreciation of both therapeutic benefits and underlying philosophy of traditional Chinese medicine. She has set up her career goal as “I have come a long way to reach my decision to study the life science in college…. I will work hard to bridge western medical and advancement with traditional eastern practices.” Iris also demonstrated leadership potential through her role of co-captain in organizing and configuring the school math team which helped each team member to perform to their best. With admission offers from many top schools, Iris has decided to attend Princeton University next fall.

Camilla Yu

- Cumulative GPA: 4.36, SAT Scores: 1560 (Verbal and Math)
- Honor/High Honor Roll Student-1996 to present
- Award of Excellence in Massachusetts State Science Olympiad Tournament
- 1st place in 17th Annual BU College of Engineering and Design Competition Champion
- Danced with Boston Ballet and performed in the Nutcracker

Camilla Yu is graduating from Newton South High School. Since 1996, she has been an Honor Roll student. As one of her many notable awards, she ranked 1st place (with $20,000 scholarship) in 17th Annual BU College of Engineering and Design Competition. Outside of class, Camilla is a versatile and active individual, from participating in science and math teams at school to winning the Presidential Community Service Award in the community. She is an accomplished dancer, both of traditional Chinese dance and contemporary Western dance. She has recently won 1st place in the Fourth New England Chinese Dance Competition. She has a clear career goal in the field of human health care and humanities. Her alertness and attention for the welfare of others is evidenced by her role as president and founder of the Newton South Chapter of Active Minds on Campus, a national collegiate organization for promoting awareness about mental health. Camilla has decided to attend McGill University to start the new chapter of her life.
Corporate Sponsors of the SAPA-NE 14th Annual Conference

Merck & Co., Inc.

At Merck, we work hard to keep the world well. How? By providing people all around the globe with innovative prescription medicines, vaccines, and consumer care and animal health products. We also provide leading healthcare solutions that make a difference. And we do it by listening to patients, physicians and our other partners — and anticipating their needs.

Not just healthcare.

HUMANCARE

We believe our responsibility includes making sure that our products reach people who need them, regardless of where they live or their ability to pay. So we’ve created many far-reaching programs and partnerships to accomplish this. You can learn more about them at merck.com.

We continue on our journey to redefine ourselves to bring more hope to more people around the world. Our goals are clear and our commitment is fierce. We are dedicated to solving problems and pursuing new answers.
Novartis Institutes for BioMedical Research

The Novartis Institutes for BioMedical Research (NIBR) is Novartis’ global research organization. Headquartered in Cambridge, Massachusetts, USA, and with research facilities around the world, its mission is to develop innovative medicines for patients worldwide.

Scientists at Novartis Institutes are blazing a new path in drug discovery by integrating various scientific disciplines, fostering interaction among scientists from within and outside of Novartis, and developing partnerships with academic research institutions and biotechnology companies to move beyond the traditional boundaries of translational research. Research at Novartis Institutes begins and ends with the patient.

Recent scientific advances, such as the sequencing of the human and other genomes, have catalyzed a unique opportunity for discovering drugs that can address the underlying causes of disease. Novartis Institutes is capitalizing on such advances by positioning itself at the intersection of genomics and medicine. Novartis’ key attributes include scientifically focusing on medicines to address the basic molecular mechanisms underlying disease, organizationally pursuing a comprehensive, multi-disciplinary structure built around human genetics, model systems, imaging technologies, and chemical diversity, and culturally building activities on extensive and deep collaborations with scientific innovators in academic organizations and biotechnology companies.

Novartis Institutes currently has areas of concentration in; cardiovascular disease; dermatology/immunopathology; diabetes and metabolism; genetic therapy; infectious diseases; nervous system disorders; oncology; musculoskeletal; respiratory diseases; and transplantation.

Research at Novartis Institutes is truly a worldwide endeavor, with research facilities located in the following locations: Basel, Switzerland; Horsham and London, UK; Vienna, Austria; Tsukuba, Japan; East Hanover, NJ; Novartis Institutes Headquarters, Cambridge, MA, USA.
Millennium-Takeda

We Aspire to Cure Cancer

Boston Globe's 2008 Best Places to Work

Millennium: The Takeda Oncology Company combines the innovative science of a leading American biopharmaceutical company with the global assets – both intellectual and fiscal – of Japan's largest pharmaceutical company. We are focused exclusively in oncology to improve the treatment of cancer around the world.

Our People and Culture
Millennium employs more than 1,100 people at our headquarters in Cambridge, Massachusetts. To us, our work is more than a job. We are driven by our passion for people and progress, so we're intense about our work. But we're also caring and fun, and enjoy one another.

Our History
Millennium Pharmaceuticals, Inc., was established in 1993 as a genomics company applying world-class recombinant technology to the discovery and development of innovative new therapies in a broad spectrum of diseases. Millennium has since grown into a fully integrated biopharmaceutical company with a pipeline of investigational drug candidates. In May of 2005, the company's leadership changed as Founder Mark Levin turned the helm over to his carefully selected successor, Deborah Dunsire, M.D. In May, 2008, Millennium was acquired by Takeda Pharmaceutical Company Limited. Takeda is the largest pharmaceutical company in Japan, and a global enterprise with an important presence in key markets. Millennium now operates as an independent subsidiary, serving as the global center of excellence in oncology under its new name: "Millennium: The Takeda Oncology Company."

Pipeline
Our top priority is to develop and bring to market new drug candidates that improve patients' lives. Our ultimate goal is to find cures for cancer.
Simcere Pharmaceutical Group: Living up to the patient expectations

Simcere Pharmaceutical Group was incorporated on March 28, 1995. In the sixteen years since its inception and with over 4,000 employees nationwide, Simcere has become a fully integrated pharmaceutical enterprise with a leading R&D organization, six GMP manufacturing facilities and strong sales and marketing capabilities.

On April 20, 2007, Simcere successfully debuted on the NYSE (ticker: SCR) as the first NYSE-listed biopharmaceutical company from mainland China.

On July 21, 2011, Simcere made yet another pioneering strategic move by signing a framework agreement with Merck & Co. to form a joint venture in China to develop, manufacture, and commercialize branded generic drugs. By combining the strength of a multinational pharmaceutical company and a local leading player, this first-of-its-kind partnership aims to broaden market access to quality medicine for Chinese patients.

Simcere’s product portfolio includes more than 45 differentiated products covering the therapeutic areas of oncology, cerebrovascular diseases, cardiovascular diseases, infection and inflammation. Among its in-line portfolio, Endostar is a novel recombinant human endostatin approved for treatment of lung cancer. Bicun (Edaravone Injection) was the first anti-stroke drug launched in China and is widely used as a standard treatment in after-stroke management. It is recognized as a ‘Well-known Chinese Trademark’. Moreover, Yingtaiqing and Zailin are also recognized as ‘Well-known Chinese Trademarks’. In 2009, Yingtaiqing became a promotion partner of the NBA in the China market. Furthermore, Simcere’s generic diosmectite marketed under the brand name “Biqi” for the treatment of diarrhea has passed EU-GMP inspection for both its formulation and API manufacturing in 2011 and is authorized to market and sell in the EU countries.

Simcere’s Research and Development Institute was established in 2004. Its capabilities include early stage discovery, medicinal chemistry, antibody discovery, preclinical development, CMC and process development, clinical operations and regulatory affairs. Since 2007, Simcere R&D has filed for 60 patent applications, including 6 PCT applications. In addition, Simcere R&D has obtained 18 NDA approvals and 26 IND approvals. In 2011, Simcere revealed its expanded R&D Center at its headquarters in Nanjing, and the new facility has over twenty-six thousand square meters and houses the most advanced pharmaceutical research and development technologies.

Simcere’s R&D strategy is focused on developing innovative and first-to-market medicine for diseases with high mortality and morbidity. The key objective of Simcere’s research and development efforts is to deliver medicine to meet the high unmet medical needs in the therapeutic areas of oncology, neuroscience, cardiovascular and metabolic disease, infectious disease and inflammation. There are currently over twenty programs under development in Simcere’s R&D pipeline, five of which entered Class I IND filing last year and are expected to enter the clinic later this year. In August, 2011, Simcere received the approval from the SFDA to manufacture and market Iremod (iguratimod tablet) for the treatment of rheumatoid arthritis. It is a first-to-market drug independently developed by Simcere, and clinical studies demonstrate that Iremod can significantly alleviate symptoms caused by active rheumatoid arthritis.

Externalization is a critical part of Simcere’s R&D strategy. In 2009, Simcere entered a licensing and co-development partnership with Epitomics, a biotech company based in San Francisco, U.S. to develop a novel rabbit-based monoclonal antibodies. In the same year, Simcere entered an agreement with OSI, leading biotech company in the U.S., to develop a novel chemical compound for oncology indications. Last year, Simcere further expanded its R&D collaboration network by entering into a strategic partnership with Bristol-Myers Squibb Co. Ltd. (BMS) to develop a novel oncology compound. Under this partnership, Simcere will be granted the exclusive rights in China to develop and commercialize a compound developed by BMS.

Simcere’s mission is to lead the development of innovative medicine in China, to provide effective treatment to serious disease, and to better the lives of the Chinese people. We are committed to serve our patients, physicians, and communities with pride, compliance, and the utmost integrity.
Zhongguancun Life Science Park

The Zhongguancun National Demonstration Zone dates back to the "Zhongguancun Electronics Street" in the early 1980s. In May 1988, the State Council approved the establishment of the Beijing New Technology Industrial Development Trial Zone. Thus Zhongguancun became the first high-tech park in China.

On March 13, 2009, the State Council approved the construction of the Zhongguancun National Demonstration Zone, and made the plan to build Zhongguancun a S&T innovation center with a global influence. Later the Development Plan Outline for Zhongguancun National Demonstration Zone (2011-2020), was launched by the State Council on Jan 26, 2011, marking a new starting point for Zhongguancun's development.

During the past two decades, Zhongguancun has gathered nearly 20,000 high and new-tech enterprises, represented by Lenovo and Baidu, and has formed a high and new-tech industrial cluster featuring electronic information, biomedicine, energy and environmental protection, new materials, advanced manufacturing, aerospace, R&D and service.

Zhongguancun is the most intensive scientific, education and talent resource base in China. It boasts almost 40 colleges and universities like Peking University and Tsinghua University, more than 200 national (municipal) scientific institutions. Zhongguancun is one of the "innovation and entrepreneurial base for overseas talents" conferred by the Central Personnel Work Coordination Group. There are more than 5,000 enterprises with at least 15,000 overseas returnees. The entrepreneur representatives include Lenovo president Liu Chuanzhi and Li Yanhong, president of Baidu, and Kai-Fu Lee, Google Greater China's former CEO and the president of Innovation Works.

To meet the national strategic requirements and Beijing's needs for socioeconomic development, Zhongguancun has obtained a large number of key technical breakthroughs, innovation results and critical S&T innovations, such as the super computer, human vaccines against SARS and bird flu. Zhongguancun also provided technical support for the implementation of major state construction projects, including aerospace engineering, the Three Gorges Project, and the Qinghai-Tibet Highway construction.

Zhongguancun enterprises have formulated 86 important international standards like TD-SCDMA, McWill and IGRS, and 798 national, local and industrial standards. Its technology transaction values exceed a third of the country's total, including 80 percent of project products and services exported outside Beijing.

In 2010, the gross income of enterprises in Zhongguancun achieved 1.59 trillion yuan, an increase of 22.6 percent, taking up about one seventh of all high and new-tech zones in China and contributing 23.5 percent to Beijing's economic growth.

Currently, Zhongguancun is home to 10 parks, namely, Haidian, Fengtai, Changping, Electronics City, Yizhuang, Desheng, Yonghe, Shijingshan and Tongzhou Parks as well as the Daxing Biomedicine Industrial Base.

During the 12th Five-Year Plan period, Zhongguancun will further improve its Science and Future S&T Cities, promote the development of the northern R&D service and high-tech industrial belt, which are located in North Haidian, South Changping, as well as the southern high-tech manufacturing and emerging industrial belt.

The Zhongguancun Demonstration Zone will further open to the world and serve Beijing as it develops into a global city. Plans for the demonstration zone include an international science and technology innovation center to be built within a decade.
Celgene Corporation

Celgene: a global biopharmaceutical company committed to improving the lives of patients worldwide

Our Mission: At Celgene, we are focused on our mission - delivering innovative therapies to patients with unmet medical needs in cancer and inflammatory diseases.

Our People: Celgene employs more than 4,500 employees worldwide. Celgene has been attracted employees of the highest caliber since its earliest days. We believe that our ongoing success will enable us to maintain this extraordinary level of commitment and to continue to attract the best people at every level of the organization.

Our History: Celgene was initially founded as a unit of the Celanese Corporation in 1980. Following the 1986 merger of Celanese Corporation with American Hoechst Corporation, Celgene was spun off as an independent biopharmaceutical company.
Frontage Laboratories, Inc

Frontage Laboratories, Inc. is a global contract research, development and manufacturing organization, offering a full range of pharmaceutical R&D services. Frontage operates in the US and China, using one seamless GXP platform (GMP/GLP/GCP). Frontage runs three Phase 1 Clinical units, an 88-bed Phase 1 Unit in Hackensack, NJ, a 120-bed Phase 1 Unit in Zhengzhou, Henan Province China, and a 80 bed Phase 1 Unit in Changchun, Jilin Province China. Frontage has an AALAC certified preclinical animal facility in Pennsylvania, where it also maintains bioanalytical and CMC facilities. In Shanghai and Beijing, China, the company also operates bioanalytical and CMC facilities. The Frontage CMC Division provide services in the areas of custom API synthesis and GMP manufacturing, analytical testing, formulation development and manufacturing of clinical trial materials including Sterile (Injection and Ophthalmic), Oral Solid (IR and CR), Topical, and High Potent products. As a rapidly expanding CRO with ten years of success providing high-quality GXP services, Frontage has established an international standard in pharmaceutical product research, development, quality and management systems.

Livzon MabPharma Inc

Livzon Corp., headquartered in Zhuhai, China, is a fully integrated generic company. It was found in 1985, and went public in ShenZhen Stock Exchange in 1989. The company has over 5,000 employees, currently. It ranks among the top 50 in China.

The company has over 500+ product forms, which include gastrointestinal, anti-infectious (antibacterial, antiviral), cardiovascular, anti-cancer, immunomodulant, reproductive, neurological, urological, dermatological and pediatric agents.

The total assets, net assets and annual revenue are approximately $615 mil, $415 million and $430 mil, respectively.

In terms of geographic location, the company is situated next to Macao, Hong Kong (1 hour by ferry), Guangzhou (2-hour by car), and ShenZhen (1 ½ hour by car).

Livzon MabPharm, Inc. (LMI) was found in June 2010, a fully own subsidiary of Livzon Corp. The goal is to transform the currently business model from a small molecule generic company to a fully integrated biopharmaceutical company in 10 years. LMI focuses on developing and producing biosimilar and bio-better candidates.

Currently, LMI has 50+ employees, and by this summer, the number of employees will increase to 70+ people. LMI is headed up by Dr. Fu Daotian, former Genzyme VP. The R&D group is led by Dr. Peng Yucai, former Biogen-Idec Senior Scientist. The Manufacturing and Technical Operations group is headed up by Alan Wong, former Regeneron Director.
The new antibody building exterior and the interior design were complete. Major equipment like fermenter, purification system, filling line, lyophilizer, sterilizer, etc. are being procured. All the equipment should be installed by 2Q 2013. The entire building is expected to be occupied by 3Q 2013, and the 1st GMP run is expected to be performed by Oct 2013.

LMI is actively recruiting senior positions in Director level in cell culture/fermentation, purification, and fill/finish areas.

**Wuhan BridgeBio Introduction**

Carrying the mission of bridging the best life science technologies to fast growing China economy, BridgeBio International Group (BridgeBio) is a specialized life science park and investment management company founded by a group of oversea Chinese returnees, mostly from US, who have many years of R&D, investment and entrepreneurial experience. BridgeBio has successfully provided strategic consulting and planning services for ministry of science and technology, and industrial parks of state and provincial level. Successful cases include Tianjin International Joint Academy of Biotechnology and Medicine, Sichuan WenJiang Health Industry City, Wuhan Biolake Park, Jiangyin BridgeBio International Biotechnology Incubation Park, etc. Under our management, Jiangyin BridgeBio Biotechnology Incubation Park has incubated over 40 life science companies of which 7 have entered commercialization stage, therefore has been recognized as the “Ideal place for oversea returning entrepreneurs” by “China Entrepreneur” magazine. By leveraging favorable government policies, fully equipped labs, and well designed service alliance program, BridgeBio has designed its unique business and service model to partner with companies and to accelerate their business growth. Through years of solid work, BridgeBio has gained its reputation and position as “international bridge” and is attracting more and more companies to realize their dreams within BridgeBio.

Contact information:
Email: George.li@bridgebio.cn / Phone:+86-27-59368673 / Fax:+86-59368675

**Nexcelom Bioscience LLC**

Nexcelom Bioscience has focused exclusively on providing automated cell counting and analysis solutions. These solutions have delivered greater efficiency and more reliable data than traditional manual methods, yet are affordable and easy to use. After many customers, including researchers at the National Institute of Health, expressed the desire to automate cell counting, Nexcelom Bioscience delivered the Cellometer Auto T4, the smallest,
fastest and simplest automatic cell counting solution on the market in 2006. The company was able to accomplish this by drawing on its collective experiences in instrument design and manufacturing, medical imaging software development, and optical polymer product design and production. With continuous product innovation, the company adds new levels of sophistication to cell counting and analysis to research scientists in cancer research, stem cell research, drug discovery, and beyond. In 2008 and 2009, Cellometer Vision and Cellometer Auto X4 were introduced to provide fluorescence imaging cytometry, most suitable for cell concentration and viability of primary cells such as PBMCs, splenocytes and other digested tissues, as well as for cell-based assays such as cell cycle analysis and apoptosis.

Nexcelom Bioscience was founded in 2003 by Jean Qiu, Ph.D, who serves as its Chief Technology Officer, and Peter Y. Li, PhD President & CEO. The founders brought extensive backgrounds in scientific research and product innovation experience, through working with Fortune 50 companies. The company integrates a dynamic team for product development, manufacturing, marketing, sales, and customer service, with its headquarters in Lawrence, Massachusetts.

Nexcelom Bioscience was honored as an Inc 500 Company in 2009, as one of fastest growing private companies in America by Inc Magazine.

GenScript Incorporation

Your Innovation Partner in Drug Discovery

The pharmaceutical industry is facing unprecedented competitions and challenges. Introduction of new medicines of safety and efficacy to the market is crucial to the growth and success of the business, but the pharmaceutical R&D output has declined in an alarming rate. Imperative challenges consist of shortening target identification and validation process, developing quality assay and screening, improving compound profiling and optimization, increasing success rate while containing cost, and bringing new therapy to market continuously, thus remaining productive and competitive.

GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services. Built on our assembly-line mode, one-stop solution, continuous improvement, and stringent IP protection, GenScript provides a comprehensive portfolio of services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development which can be effectively integrated into your value chain and your operations. Headquartered in New Jersey, USA and with a major subsidiary in China, GenScript has over 800 employees, many of them are seasoned R&D scientists from leading western pharmaceutical and biotech companies with extensive experience in advancing drug discovery and development programs. We strive with competence and confidence to meet your demand for developing pre-clinical drug candidates time-efficiently and cost-effectively. With track performance record, GenScript is your ideal and reliable innovation partner in drug discovery.
Novoprotein Scientific INC is a **protein-centric** biotech company which offers a comprehensive portfolio of custom protein services and carries a catalog of 750 plus cytokine/recombinant proteins.

Incorporated in 2004, Novoprotein is the first protein production CRO in China. After eight years in business, the company has accumulated extensive experience and possessed advanced technology in the field. The service scope includes protein expression, process development, custom antibody production, protein modification, and protein crystallization. The capacity of the four well-established protein expression systems: *E.coli*, yeast, baculovirus/insect cell and mammalian cell systems, has reached gram scale. Novoprotein has built its successful track record with an impressive 85% success rate over 1100 projects. The company has retained large pharma partners and biotech companies including GSK, Astrazeneca, Roche, Novartis and others over years.

Novoprotein products cover a broad range of biological aspects from immunology, stem cell, oncology and neurobiology. Novoprotein has an overall 95% customer satisfaction rate for its quality, service and cost.

Recently GEN news reported the opening of Novoprotein US office in Short Hills, NJ for US marketing. The US office has further improved smooth communication between the customers and the company, and increased the direct exposure of the great services the company can offer to its customer.

**Shanghi Medicilon Inc.**

**Medicilon**

Integrated Drug Discovery Services — Chemistry, Biology & Preclinical Services

Medicilon integrated services across biology, chemistry and preclinical services are specially designed to help clients develop their research and discovery programs from the initial idea stage to the IND filing phase.

**Preclinical Services**
- **Pharmacokinetics Services** (Pharmacokinetics, Bioanalysis, *In Vitro* ADME, Isotope Research Service, Pharmacokinetics package for IND filing)
- **Pharmacology Services** (Cancer Xenograft Models, Neurological Disorders Models, Inflammation & Immunological Disease Models, Metabolic Disease Models)
- **Toxicology Services** (Toxicology, Histology Capabilities, Clinical Pathology Capabilities)

**Biology Services**
- **Structural Biology Services** (Molecular Biology, Crystallization & Structural Determination, Computational Biology & Molecular Modeling)
Discovery Biology Services (Cell Biology & Biochemistry, Enzymatic-Based Assay, Cell-Based Assay)

Chemistry Services
Medicinal Chemistry, Custom Synthesis, Scale up Synthesis, Library Synthesis, Analytical Chemistry, Formulation Services

Integrative Services
• Hit→IND Filing • Lead Optimization→IND Filing • Pre-clinical Candidate→IND Filing

Please check www.medicilon.com for more information.

Shandong International Biotechnology Park (BiOasis)

“BiOasis Brief Introduction” Shandong International Biotechnology Park (BiOasis) is established in collaboration by Shandong provincial government, Yantai municipal government, Yantai High-Tech Zone and Shandong Luye Pharma Group, and it is the “National Innovative Drug Breeding Bases” mainly established by Shandong Province.

Near the sea and located in the core area of Yantai High-Tech Zone, BiOasis will provide a nice, natural environment suitable for both R&D and living, which will suit the needs of scientists who wish to have a perfect work-life balance. BiOasis is scheduled to establish three major areas, i.e., R&D Area, Living Area and Marina Resort, covering 172 acres with a planned building area of 1,313,400 m2 and research area of 714,800 m2. BiOasis will focus mainly on the three areas of research and development: biological medicine, ocean biology, and biological agriculture.

BiOasis is designed by internationally renowned zone-design companies according to international standards and conventions. Now in the phase I of construction, the research and development area of 100,000 m2 will be completed in 1 to 2 years, with the 10,000 m2 laboratory space being completed in half a year, and the first-phase projects can move into the zone around August 2011. Phase II and III constructions will establish 450,000 m2 biotechnology research laboratories. To attract talents from China and overseas, the zone has set up various favorable policies, such as providing seaside apartments, project start-up funds, room subsidies for research, seed fund, loan guarantee, and so on, in addition to all kinds of standard services the Zone also provides. More information about BiOasis can be found on the website www.bioasis.cn.

ShanghaiBio

ShanghaiBio Corporation is a leading biotech with lab operations at Shanghai in China and at New Jersey in the U.S. ShanghaiBio performs total genomics solution services for translational medicine focusing on biobanking, Microarray, Next Generation Sequencing (NGS), and biomarker assay development and companion diagnostics for personalized medicine. ShanghaiBio has been providing quality services for most of top 20 global pharmas, Global CROs and biotech companies, and top research institutes in China and in other countries in the past decade to support their translational research, biomarker development, and clinical trials for personalized medicine.
ShanghaiBio also initiated/participated/managed/implemented a few global and China translational medicine/biomarker consortium projects (including the Asian Cancer Research Group Consortium with Pfizer, Merck and Eli Lilly).

Amongst other CROs, ShanghaiBio is offering the following total solutions to global and Chinese pharmas, biotechs, CROs, and research institutions:

1. Tissue banking and custom sample collections with comprehensive clinical data including follow up or longitudinal data
2. Microarray services (tissue microarray, Affymetrix/Illumina/Agilent gene expression, SNP/Copy Number Variation/GWAS, microRNA, aCGH, methylation arrays)
3. Next Generation Sequencing (NGS) (Whole genome re-sequencing, Whole exome sequencing, target gene deep sequencing, RNA-Sequencing, ChIP-Sequencing, DNA methylation sequencing, microRNA sequencing)
4. Bioinformatics for advanced analysis for NGS and microarray data, and biomarker correlation with clinical outcome.
5. Clinical central lab biomarker test services (CLIA/CAP compliant biobanking, qPCR, genotyping, LumineX, Elisa, IHC, FISH, Flow-Cytometry, and LC-MS)
6. Tumor models with molecular profiling data for translational oncology research and personalized medicine drug efficacy screening
7. In vitro assays for target validation with internal tumor cell line library

Bioduro, A PPD Company

BioDuro, a PPD company, is a fully integrated, end to end global life science service company with a team of 650 in Beijing, China. Our priority is to provide the highest quality services at an affordable cost without sacrificing on safety and environmental health. Our clients include over 40 pharmaceutical and biotechnology companies worldwide, and our services span the entire drug discovery process, including biology, chemistry, pharmacology, DMPK, and drug safety evaluation. Most recently through our parent company PPD, we also extended our capability to include phase I to phase IV clinical development.

Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with net sales of over US$700 million in 2011. The company has been experiencing organic growth at an annual rate of 25% in the past few years. It is recognized as the top innovative home-grown drug company, with over a dozen of new
molecular entities in clinical trials and dozens more under pre-clinical development. Hengrui’s products and R&D span over multiple therapeutic areas, such as oncology, cardiovascular and metabolic diseases, CNS, inflammation, hematology and anesthesiology.

For more information, please visit http://www.hrs.com.cn/

Sirnaomics

Sirnaomics, Inc. is a biopharmaceutical company discovering and developing novel targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology. The company was founded in early 2007 with the mission of advancing RNAi technology using multi-targeted design of small interfering RNA (siRNA) and nanoparticle-enhanced delivery.

Sirnaomics is located in the I-270 High Tech Corridor in suburban Maryland. The company has access to state-of-the-art office and laboratory space dedicated for molecular biology, cell biology, biochemistry, synthetic chemistry and robotic screening.

Sirnaomics, Inc. is dedicated to becoming a leader in the field of siRNA therapeutics with strong technology platforms for siRNA drug design and delivery system development. The company has established partnerships with multinational pharmaceutical and major biopharmaceutical companies, and has received funding through government grants, angel investors and venture capital investments. Using multi-targeted siRNA cocktail design and three-generation nanoparticle-based delivery systems the company has discovered and developed an enriched siRNA therapeutic product pipeline. The siRNA therapeutic programs at the late stage of preclinical development include a novel approach for improvement of scarless wound healing (STP705), a dual-targeted therapeutic (STP601) for treatment of diabetic retinopathy and AMD (age-related macular degeneration), a “resistance-proof” siRNA therapeutic for treatment of Influenza infection (STP702), and a cancer siRNA therapeutics (STP503) for treatment of breast cancer, etc. The company’s goal is to focus on high value creation through development and commercialization of the novel siRNA therapeutics for the major medical unmet needs and large disease markets.

As Sirnaomics’ Chinese research and development center, Suzhou Sirnaomics Pharmaceuticals Co Ltd. was founded in early 2008 and located in Biobay, Suzhou Industry Park. Suzhou Sirnaomics’ mission is to advance RNA interference (RNAi) therapeutics using multi-targeted small interfering RNA (siRNA) and nanoparticle-enhanced delivery, for development and commercialization of siRNA therapeutics to treat critical human diseases, especially for the great China market.

GENEWIZ

Founded in 1999. GENEWIZ is a contract research company that specializes in DNA sequencing, gene synthesis, molecular biology, genomics, and GLP/GMP standard DNA services. Headquartered in New Jersey, GENEWIZ is a global leader in DNA services with
laboratory operations in New Jersey, California, Maryland, North Carolina, Massachusetts and Washington in the US, and in Beijing and Suzhou in China.

GENEWIZ was named as the Business of the Year (2011) in the 100+ Employees category by NJBIZ, a leading business publication in New Jersey. GENEWIZ received an Award for Excellence in the business expansion category from the New Jersey Business Industry (NJBIA) in 2011. GENEWIZ was ranked 28th amongst New Jersey’s 50 Fastest Growing Companies by NJBIZ in 2011. Independent marketing researching firm Frost & Sullivan selected GENEWIZ, Inc. as the recipient of the Growth Strategy Leadership Award, in recognition of its high quality services and unparalleled support in the North American DNA sequencing services markets.

Shire

As one of the world’s leading specialty biopharmaceutical companies, Shire has emerged as a company fully focused on a single purpose: to enable people with life-altering conditions to lead better lives.

Through our Shire Human Genetic Therapies (HGT) business, we pursue opportunities on behalf of patients and families facing such rare diseases as Fabry disease, Hunter syndrome, Gaucher disease, hereditary angioedema, and metachromatic leukodystrophy—patients whose very lives often hinge on the discovery and delivery of extraordinary medicines. Through our Specialty Pharma business, meanwhile, we develop and distribute an innovative portfolio of treatments for patients with ADHD, ulcerative colitis, and end-stage renal disease. Our commitment throughout is on symptomatic diseases, treated by specialist physicians. We take the risks we need to take so that we might change lives for the discernible better.

We also care, at Shire, about the communities in which we live and work—about who we are and the legacy we leave behind. Through countless Corporate Responsibility initiatives, we’re making a difference by supporting programs ranging from the education of young scientists and the beautifying of natural landscapes to the reduction of CO2 emissions and the development of a green-oriented employee family.

At Shire we are perpetually planning for the future. We’re exploring new markets. We’re conversing with thought leaders. We’re listening to patients and families, to innovators and inventors. We’re asking ourselves what more we can do to make this world a healthier place and in doing so, we’re mindful of our overall cultural ethos; to be as brave as the people we help.
Vendor Sponsors of the SAPA-NE 14th Annual Conference

Wako Chemicals USA, Inc.

Mettler Toledo

Qiagen

Wyzer Biosciences

ChemPartner